Modality
Peptide
MOA
CGRPant
Target
Aβ
Pathway
STING
MDS
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
~Jan 2017
→ ~Apr 2018
Phase 3
~Jul 2018
→ ~Oct 2019
NDA/BLA
~Jan 2020
→ ~Apr 2021
Approved
Jul 2021
→ May 2029
ApprovedCurrent
NCT05137606
1,340 pts·MDS
2021-07→2029-05·Active
1,340 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-05-103.1y awayPh3 Readout· MDS
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Active
Catalysts
Ph3 Readout
2029-05-10 · 3.1y away
MDS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05137606 | Approved | MDS | Active | 1340 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ |